**Supplementary Table S3**. The status of HBV and treatment in patients on the study

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Patient ID | HBsAg (IU/ml) | HBsAb (mIU/mL) | HBcAb (S/CO) | HBV DNA (pre-infusion) | HBV DNA (post-infusion) | Entecavir treatment | Thymalfasin treatment |
| P1 | >250 | Negative | 10.5 | 3840.0 | 29.9 |  | Yes |
| P2 | >250 | 0 | 9.61 | 185.0 |  | Yes |  |
| P3 | 41.05 | 0 | 10.89 | 131.0 |  |  | Yes |
| P4 | Negative | >1000.0 | 9.27 | 68.6 |  |  |  |
| P5 | 62.06 | 2.16 | 10.68 | 1500.0 |  | Yes | Yes |
| P6 | >250 | 0 | 10.52 | 96.4 |  |  |  |
| P9 | 38.84 | 0.09 | 9.45 | 18100.0 |  |  | Yes |
| P10 | >250 | 0 | 10.79 | 1600.0 | 3880.0 | Yes |  |
| P11 | >250 | 0.27 | 10.62 | 4150.0 | 1610.0 | Yes |  |
| P13 | >250 | 0.53 | 8.09 | 21.0 | 100.0 | Yes |  |